Wednesday, September 21, 2016

Ophtho-Chloram


Generic Name: chloramphenicol (Ophthalmic route)

klor-am-FEN-i-kol

Commonly used brand name(s)

In the U.S.


  • Ocu-Chlor

In Canada


  • Ak-Chlor

  • Chloromycetin

  • Chloroptic

  • Fenicol

  • Isopto Fenicol

  • Minims Chloramphenicol 0.5%

  • Ophtho-Chloram

  • Pentamycetin Ophthalmic Solution 0.25%

  • Pentamycetin Ophthalmic Solution 0.5%

  • Pms-Chloramphenicol

  • Sopamycetin

Available Dosage Forms:


  • Solution

  • Ointment

  • Powder for Solution

Therapeutic Class: Antibiotic


Chemical Class: Chloramphenicol (class)


Uses For Ophtho-Chloram


Chloramphenicol belongs to the family of medicines called antibiotics. Chloramphenicol ophthalmic preparations are used to treat infections of the eye. This medicine may be given alone or with other medicines that are taken by mouth for eye infections.


Chloramphenicol is available only with your doctor's prescription.


Before Using Ophtho-Chloram


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of this medicine in children with use in other age groups.


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of this medicine in the elderly with use in other age groups.


Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Citalopram

  • Voriconazole

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Ceftazidime

  • Chlorpropamide

  • Cyclosporine

  • Dicumarol

  • Fosphenytoin

  • Phenytoin

  • Rifampin

  • Rifapentine

  • Tacrolimus

  • Tetanus Toxoid

  • Tolbutamide

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Proper Use of chloramphenicol

This section provides information on the proper use of a number of products that contain chloramphenicol. It may not be specific to Ophtho-Chloram. Please read with care.


For patients using the eye drop form of chloramphenicol:


  • Although the bottle may not be full, it contains exactly the amount of medicine your doctor ordered.

  • To use:
    • First, wash your hands. Tilt the head back and, pressing your finger gently on the skin just beneath the lower eyelid, pull the lower eyelid away from the eye to make a space. Drop the medicine into this space. Let go of the eyelid and gently close the eyes. Do not blink. Keep the eyes closed and apply pressure to the inner corner of the eye with your finger for 1 or 2 minutes to allow the medicine to come into contact with the infection.

    • If you think you did not get the drop of medicine into your eye properly, use another drop.

    • To keep the medicine as germ-free as possible, do not touch the applicator tip or dropper to any surface (including the eye). Also, keep the container tightly closed.


To use the eye ointment form of chloramphenicol:


  • First, wash your hands. Tilt the head back and, pressing your finger gently on the skin just beneath the lower eyelid, pull the lower eyelid away from the eye to make a space. Squeeze a thin strip of ointment into this space. A 1-cm (approximately 1/3-inch) strip of ointment is usually enough, unless you have been told by your doctor to use a different amount. Let go of the eyelid and gently close the eyes. Keep the eyes closed for 1 or 2 minutes to allow the medicine to come into contact with the infection.

  • To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). After using chloramphenicol eye ointment, wipe the tip of the ointment tube with a clean tissue and keep the tube tightly closed.

To help clear up your infection completely, keep using this medicine for the full time of treatment, even if your symptoms begin to clear up after a few days. If you stop using this medicine too soon, your symptoms may return. Do not miss any doses.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For eye infection:
    • For ophthalmic ointment dosage form:
      • Adults and children—Use every three hours.


    • For ophthalmic solution (eye drops) dosage form:
      • Adults and children—One drop every one to four hours.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Ophtho-Chloram


If your symptoms do not improve within a few days, or if they become worse, check with your doctor.


Ophtho-Chloram Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Rare - may also occur weeks or months after you stop using this medicine
  • Pale skin

  • sore throat and fever

  • unusual bleeding or bruising

  • unusual tiredness or weakness

Check with your doctor as soon as possible if any of the following side effects occur:


Less common
  • Itching, redness, skin rash, swelling, or other sign of irritation not present before use of this medicine

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common
  • Burning or stinging

After application, eye ointments may be expected to cause your vision to blur for a few minutes.


Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Ophtho-Chloram resources


  • Ophtho-Chloram Drug Interactions
  • Ophtho-Chloram Support Group
  • 0 Reviews for Ophtho-Chloram - Add your own review/rating


Compare Ophtho-Chloram with other medications


  • Conjunctivitis, Bacterial

Optiray 160


Generic Name: ioversol (eye oh VERS ol)

Brand Names: Optiray 160, Optiray 240, Optiray 300, Optiray 320, Optiray 350


What is Optiray 160 (ioversol)?

Ioversol is in a group of drugs called radiopaque (RAY dee oh payk) contrast agents. Ioversol contains iodine, a substance that absorbs x-rays. Radiopaque contrast agents are used to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (x-ray) examination.


Ioversol is used to help diagnose certain disorders of the heart, brain, and blood vessels.


Ioversol may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about Optiray 160 (ioversol)?


You should not receive ioversol if you have any type of active infection.

Tell your doctor if you have asthma, hay fever, or history of food or drug allergies, especially if you have had any type of reaction to another contrast agent.


Drink extra fluids before and after you receive ioversol. This medication can cause you to get dehydrated, which can lead to dangerous effects on your kidneys. Follow your doctor's instructions about the types and amount of fluids you should drink before and after your test.

What should I discuss with my health care provider before receiving Optiray 160 (ioversol)?


Tell your doctor if you have ever had any type of reaction to another contrast agent.


You should not receive ioversol if you have any type of active infection.

Before receiving ioversol, tell your doctor if you have:



  • a brain tumor or hematoma;




  • a recent head or brain injury;




  • epilepsy or other seizure disorder;




  • a bleeding or blood clotting disorder;




  • kidney disease;




  • liver disease;




  • diabetes;




  • heart disease, angina, or congestive heart failure;




  • homocysteinuria;




  • sickle cell disease;




  • a history of stroke, blood clots, or circulation problems;




  • asthma, hay fever, or a history of food or drug allergies;




  • multiple myeloma (bone cancer);




  • pheochromocytoma; or




  • a thyroid disorder.



If you have any of these conditions, you may not be able to receive ioversol, or you may need a dosage adjustment or special tests during treatment.


FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether ioversol passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Older adults may need special care in avoiding dehydration by drinking extra fluids before and after the radiologic test. Your kidney function may also need to be watched closely after you have received ioversol.


How is ioversol used?


Ioversol is given as an injection through a needle placed into a vein. You will receive this injection in a clinic or hospital setting during your radiologic test.


Drink extra fluids before and after you receive ioversol. This medication can cause you to get dehydrated, which can lead to dangerous effects on your kidneys. Follow your doctor's instructions about the types and amount of fluids you should drink before and after your test. Your doctor or other healthcare provider may want to watch you for a short period of time after your injection. This is to make sure you do not have any unwanted side effects or delayed reactions.

This medication can cause you to have unusual results with certain thyroid tests. If you have such tests within 16 days after receiving ioversol, tell the doctor in charge that you have recently received ioversol.


What happens if I miss a dose?


Since ioversol is used only during your radiologic test, you will not be on a dosing schedule.


What happens if I overdose?


Seek emergency medical attention if you think you have received too much of this medicine. Symptoms of an ioversol overdose may include chest pain, trouble breathing, and slow or uneven heartbeats.

What should I avoid while receiving Optiray 160 (ioversol)?


Do not allow yourself to become dehydrated during the first few days after receiving ioversol. Call your doctor if you have any vomiting or diarrhea during this time. Follow your doctor's instructions about the types and amount of fluids you should drink.

Optiray 160 (ioversol) side effects


Some of the side effects of ioversol can occur up to 24 hours after you have received the medication.


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

  • urinating less than usual or not at all;




  • severe muscle pain or weakness;




  • seizure (convulsions);




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;




  • sudden numbness or weakness, especially on one side of the body;




  • sudden headache, confusion, problems with vision, speech, or balance;




  • feeling light-headed, fainting;




  • wheezing, trouble breathing;




  • fast or slow heartbeat;




  • easy bruising, unusual bleeding, or skin changes; or




  • swelling of your hands, ankles, or feet.



Other less serious side effects are more likely to occur, such as:



  • fever, warmth, or pain;




  • skin rash or redness;




  • headache; or




  • nausea.



Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Optiray 160 (ioversol)?


There may be other drugs that can affect ioversol. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More Optiray 160 resources


  • Optiray 160 Side Effects (in more detail)
  • Optiray 160 Use in Pregnancy & Breastfeeding
  • Optiray 160 Drug Interactions
  • Optiray 160 Support Group
  • 0 Reviews for Optiray60 - Add your own review/rating


Compare Optiray 160 with other medications


  • Body Imaging
  • Cerebral Arteriography
  • Coronary Arteriography
  • Head Imaging
  • Intra-arterial Digital Subtraction Angiography
  • Intravenous Digital Subtraction Angiography
  • Intravenous Urography
  • Left Ventriculography
  • Pediatric Angiocardiography
  • Peripheral Arteriography
  • Renal Arteriography
  • Venography
  • Visceral Arteriography


Where can I get more information?


  • Your doctor or pharmacist has more information about ioversol written for health professionals that you may read.

See also: Optiray60 side effects (in more detail)


Optase


Generic Name: balsam Peru, castor oil, and trypsin topical (BAL sum pe ROO, KAS tur oyl, TRIP sin TOP i kal)

Brand Names: Allanderm-T, Granul-Derm, Granulex, Optase, Revina NLT, TBC, Trypsin, Vasolex, Xenaderm


What is balsam Peru, castor oil, and trypsin?

Balsam Peru increases blood flow to a wound area, and also helps fight bacteria.


Castor oil prevents skin cells from breaking down, which aids in wound healing.


Trypsin helps shed damaged skin cells.


The combination of balsam Peru, castor oil, and trypsin topical (for the skin) is used to treat bed sores and other skin ulcers. This medication can help promote healing and relieve pain caused by these conditions.


Balsam Peru, castor oil, and trypsin may also be used for purposes not listed in this medication guide.


What is the most important information I should know about balsam Peru, castor oil, and trypsin?


Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Some forms of this medication are flammable. Do not use near open flame or while you are smoking. Avoid inhaling the spray. Avoid getting this medication in your eyes, mouth, and nose, or on your lips. If it does get into any of these areas, rinse with water.

Use this medication regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.


What should I discuss with my health care provider before using balsam Peru, castor oil, and trypsin?


You should not use this medication if you are allergic to balsam Peru, castor oil, and trypsin. This medication is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether this medication passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use balsam Peru, castor oil, and trypsin?


Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Wash your hands before and after applying this medicine.

Apply a thin layer of medication to the wound. Balsam Peru, castor oil, and trypsin is usually applied at least twice daily. Follow your doctor's instructions.


After applying the medication, you may cover the wound with a bandage dressing, or leave the wound open to the air. Your doctor will tell you whether you should cover the wound or not.

If you need to remove this medication, wash it off with water and mild soap.


Some forms of this medication are flammable. Do not use near open flame or while you are smoking. Avoid inhaling the spray.

Use this medication regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.


Store at room temperature away from moisture and heat. Do not allow the medicine to freeze.

What happens if I miss a dose?


Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while using balsam Peru, castor oil, and trypsin?


Avoid getting this medication in your eyes, mouth, and nose, or on your lips. If it does get into any of these areas, rinse with water.

Avoid using skin products that can cause irritation, such as harsh soaps or shampoos or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime.


Avoid using other medications on the areas you treat with balsam Peru, castor oil, and trypsin unless you doctor tells you to.


Balsam Peru, castor oil, and trypsin side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Treating a skin wound may increase your risk of developing an infection in your blood. Call your doctor at once if you have any signs of infection, such as:

  • fever or chills;




  • rapid breathing, gasping for breath;




  • fast heart rate;




  • warmth under your skin; or




  • unusual weakness.



Less serious side effects are more likely, such as mild stinging or burning where the medicine is applied.


This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect balsam Peru, castor oil, and trypsin?


It is not likely that other drugs you take orally or inject will have an effect on topically applied balsam Peru, castor oil, and trypsin. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Optase resources


  • Optase Use in Pregnancy & Breastfeeding
  • Optase Drug Interactions
  • Optase Support Group
  • 0 Reviews for Optase - Add your own review/rating


  • Granul-Derm Spray MedFacts Consumer Leaflet (Wolters Kluwer)

  • Trypsin

  • Xenaderm Ointment MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Optase with other medications


  • Dermatologic Lesion


Where can I get more information?


  • Your pharmacist can provide more information about balsam Peru, castor oil, and trypsin.


Optaflexx 45





Dosage Form: FOR ANIMAL USE ONLY
Optaflexx® 45

Ractopamine

Hydrochloride

For use in Feeds For Cattle

Fed In Confinement For Slaughter Only


Net Weight 25 lb (11.34 kg)


Elanco® AF0630-25B



Type A Medicated Article



Do Not Feed Undiluted

Active Drug Ingredient: Ractopamine Hydrochloride - 45.4 g per lb (100 g per kg)



Important: Must be thoroughly mixed into feeds before use. Follow label directions.



Indication: Complete Feed: For increased rate of weight gain, improved feed efficiency and increased carcass leanness in cattle fed in confinement for slaughter during the last 28 to 42 days on feed.



Top Dress Feed: For increased rate of weight gain and improved feed efficiency in cattle fed in confinement for slaughter during the last 28 to 42 days on feed.


Note: Carcass leanness effects are not an approved indication for use when feeding ractopamine by Top Dress Feeding methods.



Complete Feed













a Based on 90% Dry Matter Basis


IndicationsAppropriate Concentration of Ractopamine in Type C Medicated FeedaRactopamine (mg/hd/d)
Increased Rate of Weight Gain, and Improved Feed Efficiency8.2 to 24.6 g/ton (9 ppm to 27 ppm)70-430
Increased Rate of Weight Gain, Improved Feed Efficiency, and Increased Carcass Leanness9.8 to 24.6 g/ton (11 ppm to 27 ppm)90-430

















































a The effect of ractopamine on parameters listed in this table is supported by data generated at the doses tested in the clinical field efficacy trials.



   NC = No Change, ↑= Increased, ↓ = Decreased



b Steers Only



c Reduction indicates an improvement in USDA Yield Grade.


Carcass MeasurementsEffect of Ractopaminea
8.2 grams/ton (9 ppm)16.4 grams/ton (18 ppm)24.6 grams/ton (27 ppm)
Hot Carcass Weight, lbs↑↑↑
Dressing Percentage, %NC↑b↑b
Carcass Percent Fat, %NC↓↓
12th Rib Fat Thickness, in.NCNCNC
Average Rib Eye Area, sq. in.↑↑↑
USDA Yield GradeNCNC↓c
Marbling ScoreNCNCNC
Rate of Carcass Lean Gain per DayNC↑↑
Efficiency of Carcass Lean Gain per DayNC↑↑

Top Dress Feed










a Based on 90% Dry Matter Basis


IndicationsAppropriate Concentration of Ractopamine in Type C Medicated FeedaRactopamine (mg/hd/d)
Increased Rate of Weight Gain and Improved Feed EfficiencyAppropriate Concentration of Ractopamine in a minimum of 1.0 lb Top Dressed Type C Medicated Feeda (maximum of 800 g/ton)70-400

Inert Ingredients: Ground corn cobs.



Mixing Directions (Complete Feed): Thoroughly mix Optaflexx 45 Type A Medicated Article in a ton of appropriate feed ingredients or diluents according to the table below to obtain the proper concentration in the Type B Medicated Feed (maximum 4,920 g/ton). The following table gives examples of how some Type B Medicated Feed concentrations can be prepared:



















a Optaflexx 45 contains 45.4g ractopamine hydrochloride per pound



b Based on 90% Dry Matter Basis


Pounds of Optaflexx 45a

To Add Per Ton To Make a Type B Medicated Feed
Resulting Ractopamine Concentration in Type B Medicated Feedb
grams/tongrams/pound 
36.11,6400.82
72.23,2801.64
108.34,9202.46

Thoroughly mix Optaflexx 45 Type A Medicated Article in a ton of complete cattle feed according to the table below to obtain the proper concentration in the Type C Medicated Feed. Prepare an intermediate pre-blend of the premix prior to mixing in a complete feed. Thoroughly mix the required amount in a convenient quantity of feed ingredients then add to the remaining feed ingredients to make one ton of complete feed.













a Optaflexx 45 contains 45.4g ractopamine hydrochloride per pound



b Based on 90% Dry Matter Basis


Pounds of Optaflexx 45a

Per Ton To Make a Type C Medicated Feed
Resulting Ractopamine Concentration in

Type C Medicated Feedb
0.188.2 grams/ton (9 ppm)
0.3616.4 grams/ton (18 ppm)
0.5424.6 grams/ton (27 ppm)

Mixing Directions (Liquid Type B Feeds): Thoroughly mix Optaflexx Type A Medicated Article in a ton of appropriate feed ingredients or diluents according to the table below to obtain the proper concentration in the Type B Medicated Feed (maximum 2300 g/ton).


Maintain supplement pH at 4.5 to 7.5. For stored liquid Type B medicated feeds containing ractopamine, recirculate immediately prior to use for not less than 10 minutes, moving not less than 1% of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not in use.


The following table gives examples of how some Type B Medicated Feed concentrations can be prepared:


















a Optaflexx 45 contains 45.4g ractopamine hydrochloride per pound


Pounds of Optaflexx 45a

To Add Per Ton To Make a Liquid Type B Medicated Feed
Resulting Ractopamine Concentration in Liquid Type B Medicated Feed
grams/tongrams/pound 
36.11,6400.82
44.12,0001.00
50.72,3001.15

Mixing Directions for Preparing Type C Medicated Top Dress Feed: Thoroughly mix Optaflexx 45 Type A Medicated Article in a ton of appropriate feed ingredients or diluents according to the table below to obtain the proper concentration in the Type C Medicated Feed (maximum 800 g/ton). The following table gives examples of how some Type C Medicated Top Dress Feed concentrations can be prepared:
































a Optaflexx 45 contains 45.4g ractopamine hydrochloride per pound



b Based on 90% Dry Matter Basis


Pounds of Optaflexx 45a To Add Per Ton To Make Type C

Medicated Top Dress Feed
Resulting Ractopamine Concentration in

Type C Top Dress Medicated Feedb
Top Dressgrams/tongrams/poundmg/pound
2.201000.0550
4.412000.10100
6.613000.15150
8.814000.20200
17.628000.40400

Directions for Use (Complete Feed): Feed continuously to cattle fed in confinement for slaughter as the sole ration for the last 28 to 42 days on feed.



Directions for Use (Type C Medicated Top Dress Feed): Feed continuously to cattle fed in confinement for slaughter a Type C Medicated Feed containing up to a maximum of 800 g/ton ractopamine (see mixing direction table) to provide 70 to 400 mg/head/day for the last 28 to 42 days on feed. Type C Medicated Top Dress feed must be fed in a minimum of 1.0 lb per head per day to provide 70 to 400 mg/head/day.


CAUTION: Not for animals intended for breeding.


NOT FOR HUMAN USE




WARNING: The active ingredient in Optaflexx, ractopamine hydrochloride, is a beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of the reach of children. The Optaflexx 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and handling Optaflexx, use protective clothing, impervious gloves, protective eye wear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes thoroughly with water. If irritation persists, seek medical attention. The material safety data sheet contains more detailed occupational safety information. To report adverse effects, access medical information, or obtain additional product information, call 1-800-428-4441.




Store at Room Temperature. Avoid Moisture.


Expiration Date and Lot Number are printed on the bag. Not to be used after the expiry date.


Restricted Drug (California) - Use Only as Directed - NADA # 141-221, Approved by FDA


Optaflexx® 45


Elanco Animal Health

A Division of Eli Lilly and Company

Indianapolis, IN 46285, U.S.A.


To report adverse effects, access medical information, or obtain additional product information, call 1-800-428-4441.

Elanco®, Optaflexx®, and the diagonal bar are trademarks of Eli Lilly and Company.


BG5850DEAMB (V03-01-2010)


Principal Display Panel

Principal Display Panel – 25lb Bag Label


Elanco® AF0630-25B


For use in Feeds For Cattle Fed In Confinement For Slaughter Only


Optaflexx® 45™


Ractopamine Hydrochloride


Net Weight 25lb


(11.34 kg)










Optaflexx 45 
ractopamine hydrochloride  granule










Product Information
Product TypeOTC TYPE A MEDICATED ARTICLE ANIMAL DRUGNDC Product Code (Source)0986-0630
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
RACTOPAMINE HYDROCHLORIDE (RACTOPAMINE)RACTOPAMINE HYDROCHLORIDE9 g  in 0.45 kg








Inactive Ingredients
Ingredient NameStrength
WATER 
SOYBEAN OIL 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10986-0630-0911.34 kg In 1 BAGNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14122106/03/2010


Labeler - Elanco Animal Health Co (807447169)









Establishment
NameAddressID/FEIOperations
Eli Lilly and Company Limited, Speke Operations230761368MANUFACTURE









Establishment
NameAddressID/FEIOperations
Eli Lilly S.A. - Irish Branch986500023API MANUFACTURE
Revised: 06/2010Elanco Animal Health Co



Operand Chg Surgical Scrub Brush


Generic Name: chlorhexidine (Topical application route)

klor-HEX-i-deen

Commonly used brand name(s)

In the U.S.


  • Betasept

  • Biopatch w/Chlorhexidine Gluconate

  • Chlorostat

  • Dyna-Hex

  • Dyna-Hex2

  • Hibiclens

  • Hibistat

  • Operand Chg Surgical Scrub Brush

  • Operand Chlorhexidine Gluconate

  • Operand Closed Loop Chg Scrub

In Canada


  • Stanhexidine Solution

  • Stanley Chlorhexidine Tinted

  • Stanley Chlorhexidine Untinted

Available Dosage Forms:


  • Dressing

  • Gel/Jelly

  • Lotion

  • Solution

  • Liquid

  • Pad

  • Sponge

  • Cream

Therapeutic Class: Antibacterial Cleansing Agent


Uses For Operand Chg Surgical Scrub Brush


Chlorhexidine belongs to a group of medicines called antiseptic antibacterial agents. It is used to clean the skin after an injury, before surgery, or before an injection. Chlorhexidine is also used to clean the hands before a procedure. It works by killing or preventing the growth of bacteria on the skin.


Before Using Operand Chg Surgical Scrub Brush


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Because of chlorhexidine's potential for causing excessive skin irritation and the risk of increased absorption through the skin, use in children less than 2 months of age is not recommended.


Geriatric


No information is available on the relationship of age to the effects of chlorhexidine in geriatric patients.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Deep or open skin wounds—Some products should not be used for this condition. Use the medicine only as directed by your doctor.

Proper Use of chlorhexidine

This section provides information on the proper use of a number of products that contain chlorhexidine. It may not be specific to Operand Chg Surgical Scrub Brush. Please read with care.


Some of the chlorhexidine products will be used in a hospital or clinic setting. The medicine will be applied by a nurse or other trained health professional.


You may be instructed to use this medicine at home. It is very important that you use this medicine only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause irritation of the skin.


Different forms of the medicine are used in different ways. Be sure you understand the directions for the product you are given before you use it. Ask your doctor or pharmacist if you have any questions.


Follow your doctor's instructions about how to clean and care for your skin before and after you use this medicine. Make sure you understand all of the directions, and ask questions if you find something is not clear.


Chlorhexidine should only be used on the skin. Do not swallow it or get it in the eyes, ears, mouth, or nose. Do not use it on the genital area (sex organs) or anal area. If it does get on these areas, rinse it off right away.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For topical dosage form (hand rinse or wipe, solution, or swabstick applicator):
    • To clean the hands (eg, Hibistat®):
      • The Hibistat® product contains large amounts of alcohol (70%) and is flammable. Apply the medicine in a well-ventilated place and do not use it while you are smoking.

      • Adults, teenagers, and children 2 months of age and older:
        • Wash your hands with soap and water. Dry your hands with a towel.

        • Rub the hands with the hand wipe for 15 seconds. Make sure to use the wipe under the fingernails and between the fingers. The medicine will dry quickly so you should not use a towel for drying. Do not wet your hands a second time.

        • Pour 1 teaspoonful (5 milliliters) of the hand rinse in your cupped hand. Rub the hands together for 15 seconds. Make sure to apply the rinse under the fingernails and between the fingers. The medicine will dry quickly so you should not use a towel for drying. Do not wet your hands a second time.


      • Children younger than 2 months of age—Use is not recommended.


    • To clean the skin or a wound (eg, Betasept®, Hibiclens®):
      • Adults, teenagers, and children 2 months of age and older—Rinse the area to be cleaned with water. Apply the smallest amount of liquid needed to cover the skin or wound area and wash gently. Thoroughly rinse the area again with water.

      • Children younger than 2 months of age—Use is not recommended.


    • To use before surgery or an injection (eg, Chloraprep®):
      • The Chloraprep® product contains large amounts of alcohol (70%) and is flammable. Do not use it on skin areas that have cuts or scrapes. Apply the medicine in a well-ventilated place and do not use it while you are smoking.

      • Adults, teenagers, and children 2 months of age and older:
        • Open the pouch and use the handle to remove the swabstick applicator. Do not touch the applicator tip. Rub the applicator on the skin with the flat side against the skin. Use a back and forth motion for 30 seconds.

        • Make sure the skin is completely wet. Let the skin air dry for one minute. Do not use a towel for drying.

        • Do not cover the treated area until the skin is completely dry. This is usually one minute or longer for hairless skin. If you must apply the medicine to a hairy area of the body, wipe the area with a towel to remove extra medicine.


      • Children younger than 2 months of age—Use is not recommended.



Storage


Ask your healthcare professional how you should dispose of any medicine you do not use.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


The Chloraprep® and Hibistat® products contain large amounts of alcohol (70%) and are flammable. Do not store them near a flame, heater, or electrical device.


Precautions While Using Operand Chg Surgical Scrub Brush


Check with your doctor if your skin problem becomes worse. Call your doctor if you have skin irritation that does not go away, such as redness, itching, or burning in the area where you used this medicine.


This medicine should not be used for an extended period of time on large areas of the body. Follow your doctor's instructions about how long to use this medicine.


This medicine may cause serious and permanent injury when placed in the eyes, ears, or mouth. Carefully follow all instructions before using this medicine to prevent serious side effects.


This medicine may cause a brown stain on clothing when chlorine is also present. These stains may not be removed by regular washing. Use only non-chlorine products to wash or bleach fabrics exposed to this medicine. If the medicine has directions on the package about washing fabrics, follow them carefully.


The Chloraprep® and Hibistat® products contain large amounts of alcohol (70%) and are flammable. Do not use them or store them near a flame, heater, or electrical device. Do not use the medicine while you are smoking. Apply the medicine in a well-ventilated place.


Operand Chg Surgical Scrub Brush Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Incidence not known
  • Blistering, burning, itching, peeling, skin rash, redness, swelling, or other signs of irritation on the skin

  • swelling of the face, hands, or feet

  • trouble breathing

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Operand Chg Surgical Scrub Brush side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Operand Chg Surgical Scrub Brush resources


  • Operand Chg Surgical Scrub Brush Side Effects (in more detail)
  • Operand Chg Surgical Scrub Brush Use in Pregnancy & Breastfeeding
  • Operand Chg Surgical Scrub Brush Support Group
  • 1 Review for Operand Chg Surgical Scrub Brush - Add your own review/rating


Compare Operand Chg Surgical Scrub Brush with other medications


  • Gingivitis
  • Mucositis
  • Periodontitis

Optison





Dosage Form: injection, suspension

WARNING: Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.


  • Assess all patients for the presence of any condition that precludes Optison administration (see CONTRAINDICATIONS).

  • In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography, and cutaneous oxygen saturation during and for at least 30 minutes after Optison administration (see WARNINGS).

  • Always have resuscitation equipment and trained personnel readily available.



Optison Description


Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is a sterile non-pyrogenic suspension of microspheres of human serum albumin with perflutren for contrast enhancement during the indicated ultrasound imaging procedures. The vial contains a clear liquid lower layer and a white upper layer that, after resuspension by gentle mixing, provides a homogeneous, opaque, milky-white suspension for intravenous injection.


Perflutren is chemically characterized as 1,1,1,2,2,3,3,3-perflutren with a molecular weight of 188, an empirical formula of C3F8 and it has the following structural formula:



Each mL of Optison contains 5.0-8.0×108 protein-type A microspheres, 10 mg Albumin Human, USP, 0.22 ± 0.11 mg/mL perflutren, 0.2 mg N-acetyltryptophan, and 0.12 mg caprylic acid in 0.9% aqueous sodium chloride. The headspace of the vial is filled with perflutren gas. The pH is adjusted to 6.4-7.4. The protein in the microsphere shell makes up approximately 5-7% (w/w) of the total protein in the liquid. The microsphere particle size parameters are listed in Table 1.







Table 1 Microsphere Particle Size Parameters
Mean diameter (range)3.0-4.5µm (max. 32.0µm)
Percent less than 10µm95%

Optison - Clinical Pharmacology



General


The Optison microspheres create an echogenic contrast effect in the blood.



Pharmacokinetics


Studies in humans have evaluated the pharmacokinetics of the perflutren component of the Optison microspheres. After injection of Optison, diffusion of the perflutren gas out of the microspheres is limited by the low partition coefficient of the gas in blood that contributes to the persistence of the microspheres. The diffusion rate has not been studied.


In an anesthetized dog model, the acoustic properties of Optison were established at 0.6 mechanical index and 2.5 MHz frequency.


Neither the pharmacokinetics of the intact microspheres or of the human albumin component have been evaluated in humans.


Metabolism

Perflutren is a stable gas that is not metabolized. The human albumin component of the microsphere is expected to be handled by the normal metabolic routes for human albumin.


Perflutren Elimination

Following a single intravenous dose of 20 mL Optison to 10 healthy volunteers (5 men and 5 women), most of the perflutren was eliminated through the lungs within 10 minutes. The recovery was 96% ± 23% (mean ± SD), and the pulmonary elimination half-life was 1.3 ± 0.69 minutes (mean ± SD). The perflutren concentration in expired air peaked approximately 30-40 seconds after administration.


Perflutren Protein Binding

The binding of perflutren to plasma proteins or its partitioning into blood cells have not been studied. However, perflutren protein binding is expected to be minimal due to the low partition coefficient of the gas in blood.


Special Populations

The pharmacokinetics of Optison have not been studied in patients with hepatic or respiratory diseases.



Gender, Age, Race


The effects of gender, age, or race on the pharmacokinetics of Optison have not been studied.



Drug-Drug Interactions


Drug-drug interactions for Optison have not been studied.



Pediatrics


The pharmacokinetics of Optison in pediatric patients have not been studied.



Pharmocodynamics


The general acoustic properties of Optison are similar to those of ALBUNEX®. The acoustic impedance of the Optison microspheres is much lower than that of the blood. Therefore, impinging ultrasound waves are scattered and reflected at the microsphere-blood interface and ultimately may be visualized in the ultrasound image. At the frequencies used in adult echocardiography (2-5 MHz), the microspheres resonate which further increases the extent of ultrasound scattering and reflection.


As assessed by the unblinded investigators in clinical studies, the median duration of Optison contrast enhancement for each of the four doses of Optison (0.2, 0.5, 3.0, and 5.0 mL) were approximately one, two, four, and five minutes, respectively (see CLINICAL TRIALS section).



Clinical Trials


The efficacy of Optison was evaluated in two identical multicenter, dose escalation, randomized, cross-over studies of Optison and ALBUNEX®. The test drugs were administered single blind and the image analysis was double blind. Eligible patients were undergoing routine echocardiography and all patients were required to have at least two of six segments of the left ventricular endocardial border that were not well delineated in the apical 4-chamber view. In these studies, the 203 patients (Study A: n=101, Study B: n=102) received at least one dose of study drug had the following characteristics: 79% men, 21% women, 64% White, 25% Black, 10% Hispanic, and 1% other race or ethnic group. The patients had a mean age of 61 years (range: 21 to 83 years), a mean weight of 196 lbs (range: 117 to 342 lbs), a mean height of 68 inches (range: 47 to 78 inches), and a mean body surface area of 2.0m2 (range: 1.4 to 2.6m2). Approximately 23% of the patients had chronic pulmonary disease, and 17% had congestive and dilated cardiomyopathy with left ventricular ejection fractions (LVEFs) of between 20% and 40% (by previous echocardiography). Patients with a LVEF of less than 20% or with New York Heart Association Class IV heart failure were not included in the studies.


The study test drugs were four doses of Optison (0.2, 0.5, 3.0 and 5.0 mL) and two doses of ALBUNEX® (0.08 and 0.22 mL/kg). The two test drugs were administered to the patients in a random sequence, with two to ten days between each drug. After non-contrast imaging, the test doses were administered in ascending order with at least ten minutes between each dose. Ultrasound settings were optimized for the baseline (non-contrast) apical four-chamber view and remained unchanged for the contrast imaging. Static echocardiographic images and video-tape segments were interpreted by a reader who was blinded to the patient's clinical history and to the identity and dose of the test drug. The primary efficacy endpoint was left ventricular endocardial border delineation, assessed before and after Optison administration, by the measurement of visualized endocardial border length. The six segments of the left ventricular endocardial border were also assessed qualitatively (i.e., not well delineated, average delineation, good delineation, excellent delineation) before and after Optison administration.


In comparison to non-contrast ultrasound, Optison significantly increased the length of endocardial border that could be visualized both at end-systole and end-diastole (see Table 2). In these patients there was a trend towards less visualization in women. Similarly, in comparison to non-contrast ultrasound, Optison significantly improved the qualitative ability to delineate each of the left ventricular segments, though the effect was less for the septal segments. As assessed by videodensitometry, Optison increased left ventricular opacification (peak intensity) in the mid-chamber and apical views (see Table 3). In subset analysis, Optison tended to enhance the quality of the spectral Doppler signal of the pulmonary veins. The imaging effects of Optison on endocardial border delineation and left ventricular opacification tended to be qualitatively similar in patients with and without pulmonary disease or dilated cardiomyopathy.


In these studies, quantitative measures of left ventricular function (e.g., ejection fraction), quantitative measurements of anatomical structures (e.g., wall thickness), or the evaluation of myocardial perfusion were not performed.









































































Table 2 Left Ventricular Endocardial Border Length Before and After Optison*,†
Length at End-Systole (cm)Length at End-Diastole (cm)
Optison dosenmean ± S.D.nmean

*

The differences in the number of enrolled patients and evaluated patients at each dose reflects exclusions based on withdrawal from the trial, or those with technically inadequate or missing images.

†

An intent-to-treat analysis, with non-favorable values imputed for missing patients, provided qualitatively similar results.

Study A (n=101)
0 mL (baseline)877.7 ± 3.0869.3 ± 3.4
0.2 mL8511.7 ± 4.38515.7 ± 3.8
0.5 mL8612.0 ± 4.99115.8 ± 5.1
3.0 mL8712.3 ± 4.48816.7 ± 4.0
5.0 mL8912.7 ± 4.99016.6 ± 4.3
Study B (n=102)
0 mL (baseline)898.1 ± 3.4899.6 ± 3.7
0.2 mL9011.3 ± 4.59515.0 ± 5.3
0.5 mL9512.4 ± 4.99716.4 ± 4.6
3.0 mL9412.6 ± 4.89916.5 ± 4.7
5.0 mL9213.0 ± 4.59516.2 ± 5.1
































































































































Table 3 Intensity of Left Ventricular Opacification* Before and After Optison™ †,‡
Mid-ChamberApex
Intensity at

End-Diastole
Intensity at

End-Systole
Intensity at

End-Diastole
Intensity at

End-Systole
Optison dosenmean ± S.D.nmean ± S.D.nmean ± S.D.nmean ± S.D.

*

Intensity measured by videodensitometry in arbitrary gray scale units (0-255).

†

The differences in the number of enrolled patients and evaluated patients at each dose reflects exclusions based on withdrawal from the trial, or those with technically inadequate or missing images.

‡

An intent-to-treat analysis, with non-favorable values imputed for missing patients, provided qualitatively similar results.

Study A (n = 101)
0 mL (baseline)9139.5 ± 16.99140.0 ± 18.19146.7 ± 19.79146.9 ± 20.1
0.2 mL9156.7 ± 26.29155.4 ± 26.69163.2 ± 28.99161.1 ± 28.5
0.5 mL9157.3 ± 26.89057.4 ± 26.79167.0 ± 30.19064.1 ± 30.2
3.0 mL9053.9 ± 22.59055.8 ± 24.39066.1 ± 28.29061.8 ± 26.8
5.0 mL8954.7 ± 24.08957.9 ± 28.38969.1 ± 30.48963.7 ± 28.9
Study B (n = 102)
0 mL (baseline)9540.4 ± 17.49540.9 ± 17.59543.7 ± 19.99545.0 ± 19.6
0.2 mL9752.5 ± 21.09751.5 ± 20.69758.4 ± 22.29756.0 ± 22.2
0.5 mL9753.3 ± 20.79653.6 ± 21.09764.4 ± 25.39661.6 ± 26.7
3.0 mL9951.2 ± 23.69955.6 ± 24.59965.4 ± 26.39962.7 ± 25.7
5.0 mL9551.8 ± 23.89555.6 ± 24.89565.2 ± 28.19562.8 ± 28.1

INDICATIONS


Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. The safety and efficacy of Optison with exercise stress or pharmacologic stress testing have not been established.



Contraindications


Do not administer Optison to patients with known or suspected:


  • Right-to-left, bi-directional, or transient right-to-left cardiac shunts,

  • Hypersensitivity to perflutren, blood, blood products or albumin (see WARNINGS).

Do not administer Optison by intra-arterial injection.



Warnings



Serious Cardiopulmonary Reactions


Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration. The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias or respiratory failure, including patients receiving mechanical ventilation). In these patients, monitor vital signs, electrocardiography, and cutaneous oxygen saturation during and for at least 30 minutes after Optison administration. In the absence of these underlying conditions, observe patients closely during and following Optison administration.


In postmarketing use, uncommon but serious reactions observed during or shortly following perflutren-containing microsphere administration included fatal cardiac or respiratory arrest, loss of consciousness, convulsions, symptomatic arrhythmias (atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or fibrillation), hypotension, respiratory distress or cardiac ischemia (see ADVERSE REACTIONS).


Always have cardiopulmonary resuscitation personnel and equipment readily available prior to Optison administration and monitor all patients for acute reactions.



Anaphylactoid Reactions


Postmarketing reports of acute anaphylactoid reactions including shock, bronchospasm, upper airway swelling, loss of consciousness, urticaria and pruritus, have occurred in patients with no prior exposure to perflutren-containing microsphere products. Monitor all patients for signs and symptoms of anaphylactoid reactions (see ADVERSE REACTIONS).



Systemic Embolization of Optison in Patients with Cardiac Shunts


In patients with right-to-left, bi-directional, or transient right-to-left cardiac shunts perflutren-containing microspheres can bypass the pulmonary particle-filtering mechanisms and directly enter the arterial circulation resulting in microvascular occlusion and ischemia. Do not administer Optison by intra-arterial injection (see CONTRAINDICATIONS).



High Ultrasound Mechanical Index


High ultrasound mechanical index values may cause microsphere cavitation or rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. The safety of Optison at mechanical indices greater than 0.8 has not been evaluated. The safety of Optison with the use of end-systolic triggering has not been evaluated.



Precautions



General


This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral disease. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral disease or CJD have ever been identified for albumin.



Laboratory Tests


Immunologic tests of serum immunoglobulins, cytokines, and complement were monitored in a 3 week study of 20 healthy volunteers and 30 patients who received Optison or a 1% albumin control. Clinically relevant changes in the measured parameters were not noted. In another study 5 subjects received a skin test with Optison one year after receiving Optison. One subject had a positive skin test and was not given a repeat dose of Optison.



Information for Patients


Patients receiving Optison should be instructed to inform their healthcare provider if they:


  1. have a congenital heart defect, or recent worsening of heart or lung conditions;

  2. have had reactions to blood, blood products, albumin or a prior Optison administration (see CONTRAINDICATIONS and WARNINGS);

  3. may be pregnant or are nursing an infant.


Carcinogenesis, Mutagenesis, and Impairment of Fertility


Animal studies were not carried out to determine the carcinogenic potential of Optison.


The result of the following genotoxicity studies with Optison were negative: 1) Salmonella/Escherichia coli reverse mutation assay, 2) in vitro mammalian chromosome aberration assay using Chinese hamster ovary cells (CHO) with and without metabolic activation, 3) CHO/HGPRT forward mutation assay, and 4) in vivo mammalian micronucleus assay.



Pregnancy Category C



Optison administered intravenously to rats during organogenesis at doses of 0.25, 5.0 and 10.0 mL/kg/day was fetotoxic at 0.25 and 5.0 mL/kg (approximately 0.2 and 5 times the recommended maximum human dose, respectively, based on body surface area). Fetotoxicity was characterized by an increased incidence of reversible delayed pelvic ossification, the incidence of which was not related to dose. Signs of maternal toxicity at 5 mL/kg included respiratory and motor signs. Maternal death occurred at 10 mL/kg. A no observable adverse effect level (NOAEL) for fetotoxicity was not determined. Teratogenic effects were not observed at doses up to 10 mL/kg/day. The NOAEL for maternal toxicity was 0.25 mL/kg.


Optison administered intravenously to rabbits during organogenesis at doses of 0.25, 2.5 and 5.0 mL/kg/day was embryofetal toxic at 2.5 and 5.0 mL/kg (approximately 5 and 10 times the recommended maximum human dose, respectively, based on body surface area). Embryofetal toxicity was characterized by a decrease in fetal body weight and an increase in embryofetal death. Teratogenic effects (cleft palates and dilation of the lateral ventricles of the brain associated with skull abnormalities and compression deformities) were observed at 2.5 mL/kg but not 5 mL/kg. Neither the incidence nor the severity of embryofetal toxicity and teratogenicity exhibited a dose-dependent relationship. Maternal toxicity (significant suppression of body weight gain, abnormal stool) was observed at 2.5 and 5.0 mL/kg with the greatest effect observed at 2.5 mL/kg. The NOAEL for embryofetal and maternal toxicity was 0.25 mL/kg (approximately 0.5 times the recommended maximum human dose).


Adequate or well-controlled studies were not conducted in pregnant women. Optison should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers


It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when Optison is administered to a nursing woman.



Pediatric Use


Safety and efficacy have not been established in pediatric patients, or in patients with congenital heart disease (see WARNINGS).



Adverse Reactions



Clinical Trials Experience


Optison was administered in clinical studies in 279 patients. Of these patients there were 192 (68.8%) men and 87 (31.2%) women. The racial demographics were 199 (71.3%) Caucasian, 52 (18.6%) Black, 24 (8.6%) Hispanic, and 4 (1.4%) other racial or ethnic groups.


In these patients, 47 (16.8%) reported at least one adverse event. Of these one event was serious and required treatment with antihistamines for hypersensitivity manifestations of dizziness, nausea, flushing and temperature elevation. Deaths were not reported during the clinical studies.


Of the reported adverse reactions following the use of Optison the most frequently reported were headache (5.4%), nausea and/or vomiting (4.3%), warm sensation or flushing (3.6%), and dizziness (2.5%). The most common adverse events observed in clinical studies of Optison are given in Table 4.



































































Table 4 SELECTED ADVERSE EVENTS REPORTED IN ≥ 0.5% OF THE SUBJECTS WHO RECEIVED Optison™ IN CONTROLLED CLINICAL STUDIES *†

*

Patients are counted separately within each body system.

†

The body system is reported if the aggregate is ≥ 0.5%.

Details are not shown if the subsystem is not ≥ 0.5%.

No. of Patients Exposed to Optison™279
No. of Patients Reporting on Adverse Event47(16.8%)
Body as a Whole38(13.6%)
  Headache15(5.4%)
  Warm Sensation/Flushing10(3.6%)
  Chills/fever4(1.4%)
  Flu-like Symptoms3(1.1%)
  Malaise/Weakness/Fatigue3(1.1%)
Cardiovascular System12(4.3%)
  Dizziness7(2.5%)
  Chest Pain3(1.1%)
Digestive System12(4.3%)
  Nausea and/or Vomiting12(4.3%)
Nervous System3(1.1%)
Respiratory System5(1.8%)
  Dyspnea3(1.1%)
Skin & Appendages11(3.9%)
  Injection Site Discomfort3(1.1%)
  Erythema2(0.7%)
Special Senses9(3.2%)
  Altered Taste5(1.8%)

Adverse events reported in < 0.5% of subjects who received Optison included: arthralgia, back pain, body or muscle aches, induration, urticaria, dry mouth, eosinophilia, palpitations, paresthesia, photophobia, premature ventricular contraction, pruritus, rash, irritableness, hypersensitivity, tinnitus, tremor, visual blurring, wheezing, oxygen saturation decline due to coughing, discoloration at the Heplock site, and burning sensation in the eyes.


Overall the reported adverse events with Optison were similar in type and frequency to those reported in the 199 patients who received ALBUNEX®.


In the clinical dose ranging studies of 40 normal volunteers, doses higher than those recommended in the DOSAGE AND ADMINISTRATION section tended to be associated with an increased frequency of reported adverse events.



Postmarketing Experience


The following adverse reactions have been identified during the postmarketing use of perflutren-containing microsphere products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


Fatal cardiac arrests and other serious but non-fatal adverse reactions were uncommonly reported. Most of these uncommon reactions included cardiopulmonary symptoms and signs such as cardiac or respiratory arrest, hypotension, supraventricular and ventricular arrhythmias, respiratory distress or decreased oxygenation. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions (see WARNINGS).



Optison Dosage and Administration


The recommended dose of Optison is 0.5 mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. See individualization of dose below.


  1. The injection rate should not exceed 1 mL per second.

  2. Follow the Optison injection with a flush of 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.

  3. The maximum total dose should not exceed 5.0 mL in any 10 minute period.

  4. The maximum total dose should not exceed 8.7 mL in any one patient study.


Individualization of Dose


Image quality in cardiac ultrasound is a function of the acoustic window which is influenced by many variables including body habitus, intervening lung tissue, adequacy of transducer skin interface and other acoustic factors. These variables may influence the ultrasound contrast effect.


If the contrast enhancement is inadequate after the dose of 0.5 mL, additional doses in increments of 0.5 mL up to 5.0 mL cumulatively in a 10 minute period may be injected intravenously up to a maximum total dose of 8.7 mL in any one patient study.



DRUG HANDLING DIRECTIONS


FOR SINGLE USE ONLY.


Optison does not contain preservatives. Bacterial contamination with the risk of post-infusion septicemia can occur if the container has been damaged or following puncture of the rubber cap. A single vial must not be used for more than one patient. Discard unused product properly.


DO NOT USE if the container has been damaged or the protective seal and/or rubber cap have been entered.


DO NOT USE if the upper white layer is absent. This indicates that the microspheres may have been damaged and may result in poor or no echo contrast.


DO NOT INJECT air into the vial.


  1. Invert the Optison vial and gently rotate to resuspend the microspheres. This process will allow the product to come to room temperature before use.

  2. Inspect the vial for complete resuspension. Failure to adequately resuspend Optison may cause an under delivery of the microspheres, and may result in inadequate contrast.

  3. Do not use Optison if, after resuspension, the solution appears to be clear rather than opaque milky-white.

  4. Vent the Optison vial with a sterile vent spike or with a sterile 18 gauge needle before withdrawing the Optison suspension into the injection syringe.

DO NOT USE if after resuspending the Optison, the product remains clear rather than appearing opaque and milky-white.



INJECTION PROCEDURE


The time from resuspension of the Optison to injection must not exceed one minute. If one minute is exceeded, resuspend the microspheres in the syringe by gently rotating and inverting the syringe.


Before injection, provide intravenous access in a peripheral vein with a 20-gauge or larger angiocatheter. Suggested methods of administration include: a short extension tubing, heparin lock, or intravenous line, all with a 3-way stopcock.


For short extension tubing or heparin lock: fill one syringe with 0.9% Sodium Chloride Injection, USP, and flush the line for patency before and after the injection of Optison.


For a continuous intravenous line: open an intravenous line with 0.9% Sodium Chloride Injection, USP (or 5% Dextrose Injection, USP) at a slow infusion rate to maintain vascular patency. The line should be flushed immediately after injection of Optison.


DO NOT ASPIRATE blood back into the Optison containing syringe before administration; this may promote the formation of a blood clot within the syringe.



How is Optison Supplied


Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is available in a carton of five 3 mL fills in single use 3 mL vials.


NDC 0407-2707-03



STORAGE


Store Optison refrigerated between 2°-8°C (36°-46°F).


Caution: Do not freeze.


Rx ONLY



Distributed by

GE Healthcare Inc.

Princeton, NJ 08540


Manufactured by

Mallinckrodt Inc.

St. Louis, MO 63042


Optison™ is a trademark of GE Healthcare.

GE and the GE Monogram are trademarks of General Electric Company.

ALBUNEX® is a trademark of Mallinckrodt Inc.


© 2008 General Electric Company - All rights reserved.


Printed in USA


Revised May 2008


OPT-1E








Optison 
albumin human  injection, suspension










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0407-2707
Route of AdministrationINTRAVENOUSDEA Schedule    




















INGREDIENTS
Name (Active Moiety)TypeStrength
Albumin human (albumin human)Active10 MILLIGRAM  In 1 MILLILITER
perflutrenInactive0.22 MILLIGRAM  In 1 MILLILITER
N-Acetyl TryptophanInactive0.2 MILLIGRAM  In 1 MILLILITER
Carprvlic AcidInactive0.12 MILLIGRAM  In 1 MILLILITER
Sodium chlorideInactive 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10407-2707-035 VIAL In 1 CARTONcontains a VIAL, SINGLE-USE
13 mL (MILLILITER) In 1 VIAL, SINGLE-USEThis package is contained within the CARTON (0407-2707-03)

Revised: 02/2009GE Healthcare Inc.

More Optison resources


  • Optison Use in Pregnancy & Breastfeeding
  • Optison Support Group
  • 0 Reviews for Optison - Add your own review/rating


  • Optison Advanced Consumer (Micromedex) - Includes Dosage Information

  • Optison MedFacts Consumer Leaflet (Wolters Kluwer)

  • Perflutren Professional Patient Advice (Wolters Kluwer)

  • Definity Advanced Consumer (Micromedex) - Includes Dosage Information

  • Definity MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Optison with other medications


  • Burns, External
  • Hypoproteinemia
  • Pancreatitis
  • Peritonitis
  • Postoperative Albumin Loss
  • Shock